Ole Kirk

Author PubWeight™ 156.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007 12.93
2 Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003 12.23
3 Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006 9.21
4 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008 8.73
5 Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003 5.61
6 Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005 5.20
7 Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005 4.40
8 Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010 3.47
9 Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010 3.30
10 Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004 3.06
11 Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013 3.04
12 A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002 2.87
13 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010 2.85
14 All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2011 2.80
15 Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005 2.73
16 Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010 2.70
17 Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010 2.59
18 Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013 2.49
19 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008 2.27
20 Chronic renal failure among HIV-1-infected patients. AIDS 2007 2.07
21 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009 2.01
22 Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS 2009 1.81
23 Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002 1.79
24 Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011 1.68
25 The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011 1.59
26 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis 2010 1.54
27 CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012 1.54
28 Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010 1.53
29 Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005 1.52
30 Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003 1.44
31 K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003 1.42
32 The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004 1.39
33 Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill 2015 1.29
34 Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006 1.27
35 Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 2008 1.25
36 Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014 1.25
37 Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012 1.16
38 Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 2007 1.15
39 Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005 1.14
40 Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008 1.11
41 Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol 2012 1.11
42 Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003 1.04
43 Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 2014 1.03
44 The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery. Scand J Infect Dis 2002 1.00
45 HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010 1.00
46 Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 2008 0.99
47 Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013 0.98
48 Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis 2013 0.98
49 A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials 2011 0.98
50 Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004 0.96
51 Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003 0.95
52 Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. PLoS One 2012 0.95
53 Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol 2007 0.94
54 Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis 2012 0.93
55 Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002 0.93
56 Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS 2011 0.91
57 Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol 2013 0.90
58 Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 2011 0.89
59 Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antivir Ther 2004 0.89
60 TTV viral load as a marker for immune reconstitution after initiation of HAART in HIV-infected patients. HIV Clin Trials 2002 0.88
61 Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. AIDS 2014 0.87
62 Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS 2015 0.87
63 Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS 2014 0.86
64 Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther 2010 0.86
65 Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS 2015 0.85
66 Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr 2015 0.85
67 Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS 2012 0.85
68 The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. Cent Eur J Public Health 2008 0.84
69 Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006 0.84
70 Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. Eur Respir J 2013 0.83
71 Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005 0.82
72 Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infect Dis 2012 0.82
73 The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther 2012 0.81
74 Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS 2014 0.80
75 Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. J Acquir Immune Defic Syndr 2013 0.79
76 HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. BMC Infect Dis 2014 0.79
77 Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr 2010 0.79
78 Incidence of abacavir hypersensitivity reactions in euroSIDA. Antivir Ther 2008 0.78
79 Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol 2014 0.77
80 Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scand J Infect Dis 2008 0.77
81 The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS 2016 0.77
82 Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004 0.76
83 Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS 2016 0.75
84 Associations between HIV-RNA-based indicators and virological and clinical outcomes. AIDS 2016 0.75
85 Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS 2017 0.75
86 Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS 2017 0.75
87 Let us put biotechnology on the global agenda. N Biotechnol 2009 0.75